Search

Introduction. Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), constitute a group of chronic inflammatory conditions affecting the digestive system. The etiology of these conditions is complex, resulting from the interaction of genetic factors with environmental factors, lifestyle, and intestinal dysbiosis. The diagnosis is established based on clinical examination and general and specific paraclinical examinations (fecal calprotectin, digestive endoscopy). The most frequent intestinal complications are strictures for both IBDs, and in CD, fistulas and abscesses, especially perianal ones, may occur. There is no curative treatment for IBD; pharmacological therapy includes immunomodulatory drugs and monoclonal antibodies. Quality of life. To quantify patients’ quality of life more objectively, various questionnaires have been developed and implemented. Patients with IBD have significantly lower quality of life than healthy individuals. Multidisciplinary team. As IBD are chronic pathologies with a long and unpredictable course, they require high-quality management as early as possible from the time of diagnosis. The key to achieving the best outcomes is the multidisciplinary patient-oriented care. Conclusions. Evaluating the quality of life of patients with IBD is essential for several reasons. A multidisciplinary team, involving the family physician, gastroenterologist, psychologist, or other specialists, is essential for providing quality care to these patients. [ABSTRACT FROM AUTHOR]

Inflammatory bowel diseases (IBD) are a group of conditions characterized by chronic inflammation of the digestive tract segments. These diseases are multifactorial conditions with an increased prevalence in modern society, a consequence of genetic and environmental factors. The main IBD are ulcerative colitis and Crohn's disease, which have many similarities but differ by localization in the digestive tract and by the degree of histopathological damage. The groups of drugs used in the treatment of IBD are: aminosalicylates, corticosteroids, antibiotics, immunomodulators and biological agents. Although there has been a lot of progress in the treatment of these diseases, currently there is no curative treatment. [ABSTRACT FROM AUTHOR]

Chronic inflammatory bowel diseases represented by ulcerative colitis and Crohn's disease are severe digestive tract diseases with clinical, pathological or epidemilogical features with partially clarified and complex causes. Etiopathogenic factors most frequently described in the literature are immunological abnormalities, associated with genetic susceptibility and the interraction between environmental factors, microbial agents with the immune intestinal system. Both Crohn's disease and ulcerative colitis affect the intestine, but both are associated with multiple extradigestive events, among which cardiovascular damage is not unfrequently seen, but not easily recognised. Endocarditis and subendocardial abscesses may arise due to sepsis or progonged use of paranteral catheters and/or immunosuppressive agents. Myocarditis or perimyocarditis occur due to autoimmune mechanisms during the exacerbations of the digestive disease or as side effect of 5-aminosalicylic acid, ulcerative colitis having a higher risk for this complication comparing to Crohn's disease. Pericardial involvement seems to be the most common type of cardiovascular complication in digestive inflamatory diseases, caused by drugs (5-ASA, azathioprine, ciclosporine), pericardio-colonic fistulae or idiopathic. Pericarditis may sometimes be the main sign of the disease. Thromboembolic complications and coronary disease may also be considered. [ABSTRACT FROM AUTHOR]

Objectives. Study the articular involvement present in inflammatory bowel disease, mainly in Crohn disease (CD) and ulcerohaemorrhagic rectocolitis (UHRC), the genetic and immune mechanism underlying the occurrence of these disorders and their complications, response to therapy, as well as the value of the immunoserology tests. Material and methods. The group of 204 patients that were monitored, consisted of two subgroups: 50 patients with CD, and 154 patients with UHRC and have been enrolled in a prospective longitudinal study. The patients were included in the study group according to strictly established criteria, taking into account the underlying inflammatory bowel disease that triggered the respective articular disorders, have been assessed according to a protocol including both individual parameters (clinical, biological), endoscopic, histopathologic, radiographs, RMN, CT evaluation. Results. 93 patients had joint manifestations. 65 of them had developed due articular lesions in ulcerative colitis and 28 Crohn's disease. In ulcerative colitis Joint damage occurred as follows: 58.5% sacroiliitis (38 cases), ankylosing spondylitis 7.7% (5) 10.7% acute arthritis (7). In Crohn's disease were detected: sacroiliac 35.8% (10 patients), 42.9% peripheral arthritis (12), acute arthritis 7.1% (2 cases), reactive arthritis 14.2% (4) with germs Salmonella (3) and Shigella (1). In 71 patients from those with articular manifestations of detecting the presence of HLAB27. Conclusions. Joint damage was correlated with the severity, type of inflammatory bowel disease (IBD) reflecting the state of activity. Joint manifestations were detected mainly in ulcerative colitis increased, unlike the literature. [ABSTRACT FROM AUTHOR]

Idiopathic inflammatory bowel disease is a significant cause of morbidity and mortality, affecting mostly young people. It comprises two entities: Crohn's disease and ulcerative colitis. The current study attempted to establish the endoscopic features of Crohn's disease and ulcerative colitis on 37 patients, aged between 0-18 years, hospitalized in Fundeni Hospital between 1995-2004. [ABSTRACT FROM AUTHOR]